Changes in Hong Kong stocks | Xuanzhu Bio-B (02575) rose nearly 3%, and the self-developed innovative drug Xuan Yuening® was included in the 2025 National Basic Medical Insurance Catalogue for the first time

The Zhitong Finance App learned that Xuanzhu Bio-B (02575) rose nearly 3%. As of press release, it had risen 1.98% to HK$66.95, with a turnover of HK$15.1953 million.

^{According to the news, on December 8, Xuanzhu Bio-B announced that the innovative drug Pyroxil tablets (trade name: Xuan Yuening®) were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)” (2025 National Basic Medical Insurance Catalogue) for the first time.} The 2025 national basic health insurance catalogue will be officially implemented on January 1, 2026.

^{The results of this medical insurance negotiation will help the company further improve the affordability and accessibility of Xuanyue Ning® among patients, further promote the drug's market promotion and increase sales scale, and have a positive impact on the company's long-term business development.} The company will actively cooperate to promote the implementation of health insurance policies, continue to promote hospital access, expand the core market and expand market coverage, so as to continuously improve patients' access to medication.